Liquid biopsy company Grail has filed for a $100 million initial public offering, according to SEC documents.
The company, which has raised about $2 billion from investors including Amazon founder Jeff Bezos, biopharma giant Johnson & Johnson, and even a Canadian pension plan, expects to trade on Nasdaq as “GRAL.”
About the Author Reprints
